Danske Bank A S Boosts Stake in Insulet Corporation $PODD

Danske Bank A S grew its position in Insulet Corporation (NASDAQ:PODD) by 26.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,829 shares of the medical instruments supplier’s stock after buying an additional 9,074 shares during the quarter. Danske Bank A S’s holdings in Insulet were worth $12,458,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Insulet by 1.0% in the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after buying an additional 87,845 shares in the last quarter. Northern Trust Corp grew its stake in shares of Insulet by 0.5% in the third quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock valued at $218,945,000 after buying an additional 3,618 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Insulet by 37.3% in the third quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after buying an additional 156,009 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Insulet by 35.0% in the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after buying an additional 142,922 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Insulet by 0.8% in the third quarter. Ameriprise Financial Inc. now owns 494,712 shares of the medical instruments supplier’s stock valued at $152,703,000 after buying an additional 4,057 shares in the last quarter.

Insider Buying and Selling

In related news, Director Michael R. Minogue bought 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the purchase, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.36% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PODD shares. Zacks Research cut Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Weiss Ratings raised Insulet from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday. Oppenheimer dropped their price objective on Insulet from $365.00 to $300.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. Canaccord Genuity Group dropped their price objective on Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. Finally, Barclays reaffirmed an “underweight” rating and issued a $286.00 price objective on shares of Insulet in a research note on Thursday, February 19th. Eighteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average price target of $327.24.

Insulet Stock Performance

PODD opened at $175.04 on Monday. Insulet Corporation has a 12 month low of $158.35 and a 12 month high of $354.88. The stock has a market capitalization of $12.12 billion, a price-to-earnings ratio of 50.01, a PEG ratio of 1.03 and a beta of 1.20. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. The business has a fifty day moving average price of $216.37 and a 200 day moving average price of $267.14.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. During the same period in the previous year, the firm posted $1.15 EPS. Insulet’s revenue for the quarter was up 31.2% on a year-over-year basis. Sell-side analysts expect that Insulet Corporation will post 6.27 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.